Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin specific peptidase 34 (USP34) is a large cysteine protease within the deubiquitinating enzyme family, characterized by its ability to cleave ubiquitin from protein substrates. It is implicated in multiple cellular processes, including regulation of the canonical Wnt signaling pathway by deubiquitinating and stabilizing AXIN1 and AXIN2, modulation of DNA double-strand break repair through stabilization of RNF168 and histone ubiquitination, and regulation of GPCR signaling by affecting the mRNA expression and cell surface abundance of receptors such as PAR1. USP34 is predominantly localized in the cytosol and nucleus, and its dysfunction has been associated with cancer, neurodevelopmental disorders, and altered osteogenesis. No clinically approved drugs are known to directly target USP34 as of the most recent literature.
Inhibitors of USP34 would block its deubiquitinating activity, potentially destabilizing or degrading target proteins such as AXIN1/2. Modulation of the DNA damage response through interference with histone or protein ubiquitination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin specific peptidase 34 (USP34).